ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.715
      -0.08%
      Bitcoin
      64,850.66
      -0.44%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Ionis Pharmaceuticals Inc (IONS)

      7. Ionis Pharmaceuticals Inc (IONS) News

      IONS

      Ionis Pharmaceuticals (IONS)

      Ionis Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:IONS
      DateTimeSourceHeadlineSymbolCompany
      04/20/20237:05AMPR Newswire (US)Ionis to hold first quarter 2023 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
      03/29/20238:45AMPR Newswire (US)New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's diseaseNASDAQ:IONSIonis Pharmaceuticals Inc
      03/28/20237:05AMPR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
      03/27/20232:00AMPR Newswire (US)Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PNNASDAQ:IONSIonis Pharmaceuticals Inc
      03/22/202311:01PMPR Newswire (US)Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALSNASDAQ:IONSIonis Pharmaceuticals Inc
      03/08/20232:05AMDow Jones NewsIonis: FDA to Review Eplontersen in ATTRv-PNNASDAQ:IONSIonis Pharmaceuticals Inc
      03/07/20237:05AMPR Newswire (US)Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)NASDAQ:IONSIonis Pharmaceuticals Inc
      03/02/20235:20PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      03/02/20235:19PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      03/02/20235:19PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      03/02/20235:19PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      03/02/20235:19PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/28/20237:05AMPR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
      02/22/20234:43PMEdgar (US Regulatory)Annual Report (10-k)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/22/202311:16AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/22/20237:01AMPR Newswire (US)Ionis reports fourth quarter and full year 2022 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
      02/21/20237:05AMPR Newswire (US)Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual MeetingNASDAQ:IONSIonis Pharmaceuticals Inc
      02/14/20234:16PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/14/202312:44PMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/09/202311:49AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/09/202311:23AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/08/20237:05AMPR Newswire (US)Ionis to hold fourth quarter and full year 2022 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
      02/07/20235:38PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/07/20235:38PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/07/20235:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/07/20235:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/07/20235:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/07/20235:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/07/20235:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
      02/07/20235:36PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IONSIonis Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:IONS